Status:

COMPLETED

Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype

Lead Sponsor:

University Hospital, Montpellier

Conditions:

Amyotrophic Lateral Sclerosis

Eligibility:

All Genders

18-95 years

Phase:

NA

Brief Summary

The main objective of this study is to investigate the correlation between the rate of motor decline and blood levels of Vitamin D total. Secondary objectives are to investigate the relationship betwe...

Detailed Description

Amyotrophic lateral sclerosis is one of the most serious neurodegenerative disease, leading to death in 3 years by progressive paralysis of 4 limbs, speech, swallowing and breathing, and due to a prog...

Eligibility Criteria

Inclusion

  • Subject with possible, probable or definite Amyotrophic Lateral Sclerosis (ALS).
  • ALS operating for less than three years at dosage of vitamin D time.
  • Subject monitored in the center ALS of Montpellier for 6 months.
  • Subject agreeing to give his consent in writing or orally if the patient SLA is unable to write

Exclusion

  • Subject has received a Vitamine D treatment in the six months preceding the inclusion
  • Subject with a clinical condition on the inclusion day that makes it highly probable death in the year (quadriplegic patient, subject ventilated for respiratory failure in ALS, major malnutrition) or with ALSFRS-R score \<20.
  • Pregnant or breastfeeding women
  • Subject not covered by a social security scheme.
  • Subject under guardianship
  • Adult protected by the law

Key Trial Info

Start Date :

September 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2015

Estimated Enrollment :

127 Patients enrolled

Trial Details

Trial ID

NCT01823380

Start Date

September 1 2012

End Date

September 1 2015

Last Update

December 7 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

UH Montpellier

Montpellier, France, 34295